Logo image of ZENA

ZENATECH INC (ZENA) Stock Fundamental Analysis

NASDAQ:ZENA - Nasdaq - CA98936T2083 - Common Stock - Currency: USD

2.2  +0.03 (+1.38%)

After market: 2.1984 0 (-0.07%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ZENA. ZENA was compared to 285 industry peers in the Software industry. Both the profitability and financial health of ZENA have multiple concerns. ZENA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZENA had negative earnings in the past year.
ZENA Yearly Net Income VS EBIT VS OCF VS FCFZENA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

ZENA has a Return On Assets of -3.59%. This is comparable to the rest of the industry: ZENA outperforms 52.30% of its industry peers.
With a Return On Equity value of -7.09%, ZENA perfoms like the industry average, outperforming 52.65% of the companies in the same industry.
Industry RankSector Rank
ROA -3.59%
ROE -7.09%
ROIC N/A
ROA(3y)-1.17%
ROA(5y)N/A
ROE(3y)-3.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZENA Yearly ROA, ROE, ROICZENA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -2 -4

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZENA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZENA Yearly Profit, Operating, Gross MarginsZENA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 5 -5 10 -10

More info and screens

3

2. Health

2.1 Basic Checks

ZENA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZENA has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for ZENA is higher compared to a year ago.
ZENA Yearly Shares OutstandingZENA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M
ZENA Yearly Total Debt VS Total AssetsZENA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 5M 10M 15M

2.2 Solvency

ZENA has an Altman-Z score of 3.77. This indicates that ZENA is financially healthy and has little risk of bankruptcy at the moment.
ZENA has a better Altman-Z score (3.77) than 65.72% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that ZENA is somewhat dependend on debt financing.
ZENA has a Debt to Equity ratio of 0.85. This is in the lower half of the industry: ZENA underperforms 73.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z 3.77
ROIC/WACCN/A
WACC9.57%
ZENA Yearly LT Debt VS Equity VS FCFZENA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 2M -2M 4M 6M 8M

2.3 Liquidity

ZENA has a Current Ratio of 1.57. This is a normal value and indicates that ZENA is financially healthy and should not expect problems in meeting its short term obligations.
ZENA has a Current ratio (1.57) which is comparable to the rest of the industry.
A Quick Ratio of 1.57 indicates that ZENA should not have too much problems paying its short term obligations.
The Quick ratio of ZENA (1.57) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.57
ZENA Yearly Current Assets VS Current LiabilitesZENA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ZENA have decreased strongly by -1850.00% in the last year.
The Revenue for ZENA has decreased by -39.59% in the past year. This is quite bad
EPS 1Y (TTM)-1850%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-39.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZENA Yearly Revenue VS EstimatesZENA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 1M 2M 3M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZENA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZENA Price Earnings VS Forward Price EarningsZENA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

ZENA's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 872.1
ZENA Per share dataZENA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ZENA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENATECH INC

NASDAQ:ZENA (4/17/2025, 8:00:02 PM)

After market: 2.1984 0 (-0.07%)

2.2

+0.03 (+1.38%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners2.06%
Inst Owner Change0%
Ins Owners32.6%
Ins Owner ChangeN/A
Market Cap51.92M
AnalystsN/A
Price TargetN/A
Short Float %7.39%
Short Ratio0.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.14
P/FCF N/A
P/OCF N/A
P/B 6.47
P/tB 34.06
EV/EBITDA 872.1
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.06
BVpS0.34
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.59%
ROE -7.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.17%
ROA(5y)N/A
ROE(3y)-3.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA 101.7
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.57
Altman-Z 3.77
F-ScoreN/A
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)184.65%
Cap/Depr(5y)N/A
Cap/Sales(3y)19.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1850%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-39.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.42%
OCF growth 3YN/A
OCF growth 5YN/A